Clinical impact of anisotropic analytical algorithm and Acuros XB dose calculation algorithms for intensity modulated radiation therapy in lung cancer patients.

OBJECTIVE: To evaluate dose differences predicted between using Anisotropic Analytical Algorithm (AAA) and Acuros XB (AXB) in patients diagnosed with locally advanced non-small cell lung cancer (NSCLC) treated with intensity modulated radiation therapy (IMRT). METHODS: A phantom study was done to evaluate the dose prediction accuracy of AXB and AAA beyond low-density medium by comparing the calculated measurement results. Thirty-two advanced NSCLC patients were subjected to IMRT. The dose regimen was 60 Gy over 30 fractions. Effects on planning target volume (PTV) and organ-at-risk (OAR) were evaluated. Clinically acceptable treatment plans with AAA were re-calculated using AXB algorithms with two modes Dw and Dm at the same beam arrangements and multileaf collimator leaf settings as with AAA. RESULTS: Using AXB yielded better agreement with the measurements and the average dose difference for all points was about 0.5%. Conversely, using AAA showed a larger disagreement with measured values and the average difference was up to 5.9%. The maximum relative difference was between AXB_Dm and AAA for PTV dose (D98 %). The percentage dose differences of plans calculated by AAA, AXB_Dw and AAA, AXB_Dm revealed that AAA overestimated the dose than AXB. Regarding OAR, results showed significant difference for lungs-PTV. CONCLUSIONS: AXB algorithm yields more accurate dose prediction than AAA in heterogeneous medium. Differences in dose distribution are observed when plans re-calculated with AXB indicating that AAA apparently overestimates dose, particularly the PTV dose. Thus, AXB algorithm should be used in preference to AAA for cases in which PTVs are involved with tissues of highly different densities, such as lung.

Rational design of some substituted phenyl azanediyl (bis) methylene phosphonic acid derivatives as potential anticancer agents and imaging probes: Computational inputs, chemical synthesis, radiolabeling, biodistribution and gamma scintigraphy.

Bisphosphonates are widely used for treatment of osteoporosis. Recently, they have been reported to be effective anticancer agents. In this work, we designed some substituted phenyl (azanediyl) bis (methylene phosphonic acid) to be tested for their anticancer effect. Both molecular docking and dynamics studies were used to select the top ranked highly scored compounds. The selected hits showed potential in vitro anticancer effect against some cell lines. Biodistribution pattern and gamma scintigraphy were conducted to the most effective derivative (BMBP) after radiolabeling with 99mTc. Results of biodistribution and scintigraphic imaging of 99mTc-BMBP in tumor bearing mice showed a notable tumor affinity, and confirmed the targeting affinity of BMBP to the tumor tissues. As a conclusion, BMBP could act as potential anticancer agent and imaging probe.